HeartSine Technologies, now part of Stryker, advances the deployment of lifesaving defibrillation therapy for the treatment of sudden cardiac arrest in non-traditional areas of care.
HeartSine was founded in 1998 to continue innovative development of advanced lifesaving products for the treatment of sudden cardiac arrest. Our passion to innovate began in 1967, when we invented the first mobile defibrillator and changed the way the world delivered emergency care. In the years since, HeartSine has continued its passion to innovate by advancing mobile defibrillation and lifesaving technology.
Our flagship product, the HeartSine samaritan PAD (Public Access Defibrillator), which is designed for ease of use, has been deployed in thousands of facilities. As HeartSine AED products are currently available in over 30 languages and are poised to save lives in more than 70 countries, the HeartSine samaritan PAD is recognized around the world for lifesaving technology.
We are committed to providing innovative, intelligent, lifesaving solutions for the assessment and prevention of sudden cardiac death. Our mission is to:
- Expand the frontiers of medical research with patented technologies that address clinical requirements and meet the needs of the market with unsurpassed quality and reliability
- Deal with customers and suppliers with the highest level of ethics and fairness
- Employ high-quality and motivated employees and promote an optimal environment for them through respect, a good workplace and rewards
- Offer products at a fair price, strive to reduce costs and earn a reasonable profit
Research and Development
HeartSine’s technology and innovation is based on a proven history of development in the field of cardiac defibrillation that began in the 1960s. Our R&D is spearheaded by an impressive team of technology experts and renowned luminaries in the industry.
A renowned panel of key authorities in the field of resuscitation employ their wealth of clinical experience on our Clinical Advisory Board to support our development of ground breaking innovative technology. The board’s prominent members include Dr. Ben Abella, Dr. Rudi Koster, Dr. David McEneaney, Dr. Doug Weaver and Chair Prof. Jennifer Adgey.
To augment and enhance our in-house development activities, we have established links in Northern Ireland with the University of Ulster, Northern Ireland Ambulance Service, Craigavon Area Hospital and the Royal Victoria Hospital, a world renowned teaching and research hospital on our doorstep. In addition, we have initiated research with University of Texas Southwestern Medical Center, the world leading institution for the advancement of resuscitation therapies.
Stryker UK Tax Strategy
Stryker is one of the world’s leading medical device companies. Stryker is a US multi-national and is in over 100 countries around the world, including the UK group comprising sister entities. We are guided by a unifying mission: Together with our customers, we are driven to make healthcare better, and our charter values are: Integrity, Accountability, People and Performance.
Stryker’s Code of Conduct sets out what is expected and our approach to tax aligns with that. The Stryker UK entities’ tax strategy is to comply with all applicable tax regulations and related disclosure requirements. Our UK tax strategy supports the Group strategy and its charter values.
Our commitment is underpinned by the following principles:
- Relationship with government
The Stryker UK entities are committed to build a strong and constructive relationship with HMRC through an open dialogue on issues of significance and to disclose relevant information to HMRC.
- Attitude towards tax planning
The Stryker UK entities engage in operational tax planning to support the business and reflects economic and commercial activity.
We adhere to relevant tax law and we seek to minimize the risk of uncertainty or disputes. We conduct transactions between group companies on an arm’s-length basis and in accordance with current OECD principles.
- Tax risk management
The Stryker UK entities manage and controls its tax risks in a proactive manner. The global tax team operates in partnership with the UK business to identify, mitigate tax risks and seek appropriate advice from relevant professional firms. The group stay aware of changes in tax law as they affect the UK by getting support from in house tax expertise and/or third-party advisors.
The UK tax strategy plus any potential risks are reviewed regularly by the board. The operation of the strategy is managed by the Senior Accounting Officer for each entity, the global tax department, internal audit and our external advisors.
- Further information
Stryker regards this publication as complying with our duty under paragraph 22 (2) of Schedule 19 UK Finance Act 2016. This publication applies to the following legal entities: Stryker UK Limited, Stanmore Implants Worldwide Limited, Imorphics Limited, HeartSine Technologies Limited, Physio-Control UK Sales Limited, Entellus Medical Europe Limited and K2M UK limited for the financial year ending 31 December 2020. We will review and update annually.